FINDEX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,006 JPY | +0.30% |
|
+0.40% | -2.33% |
| 15/04 | Findex Disposes 10,855 Shares Worth 11 Million Yen as Restricted Stock Compensation | MT |
| 28/03 | Findex to Allot Treasury Shares Worth 12 Million Yen to Directors, Executive Officers | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.33% | 16Cr | - | ||
| -4.34% | 2.98TCr | C | ||
| +45.89% | 969.41Cr | C- | ||
| +35.58% | 449.68Cr | B- | ||
| -38.33% | 238.41Cr | C- | ||
| -16.49% | 162.92Cr | - | C+ | |
| -31.33% | 120.41Cr | B | ||
| -41.51% | 99Cr | - | ||
| +7.13% | 95Cr | C | ||
| -45.19% | 76Cr | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 3649 Stock
- Ratings FINDEX Inc.
